JTC Employer Solutions Trustee Ltd Invests $67,000 in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

JTC Employer Solutions Trustee Ltd purchased a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,547 shares of the company’s stock, valued at approximately $67,000.

Several other institutional investors have also recently bought and sold shares of IDYA. AJOVista LLC acquired a new stake in shares of IDEAYA Biosciences in the fourth quarter valued at $99,000. Exchange Traded Concepts LLC lifted its position in shares of IDEAYA Biosciences by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 4,806 shares of the company’s stock worth $171,000 after purchasing an additional 1,219 shares in the last quarter. Jump Financial LLC acquired a new position in shares of IDEAYA Biosciences during the fourth quarter worth approximately $215,000. Callan Capital LLC bought a new stake in shares of IDEAYA Biosciences during the fourth quarter valued at approximately $239,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of IDEAYA Biosciences by 405.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,453 shares of the company’s stock valued at $265,000 after purchasing an additional 5,979 shares in the last quarter. Institutional investors own 98.29% of the company’s stock.

Insider Activity

In related news, insider Michael Anthony White sold 28,500 shares of the firm’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $36.24, for a total transaction of $1,032,840.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, insider Michael Anthony White sold 28,500 shares of the stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $36.24, for a total transaction of $1,032,840.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Yujiro S. Hata sold 34,433 shares of IDEAYA Biosciences stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $41.81, for a total value of $1,439,643.73. Following the completion of the sale, the chief executive officer now directly owns 677,887 shares in the company, valued at approximately $28,342,455.47. The disclosure for this sale can be found here. Insiders sold 119,644 shares of company stock worth $4,832,228 over the last quarter. 3.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

IDYA has been the topic of several research reports. Stifel Nicolaus upped their price objective on IDEAYA Biosciences from $55.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, June 4th. Citigroup raised their price target on IDEAYA Biosciences from $40.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, March 21st. Wedbush reissued an “outperform” rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a report on Wednesday, May 8th. The Goldman Sachs Group reduced their target price on shares of IDEAYA Biosciences from $53.00 to $46.00 and set a “buy” rating on the stock in a research note on Monday, May 13th. Finally, BTIG Research initiated coverage on shares of IDEAYA Biosciences in a research report on Friday, March 8th. They set a “buy” rating and a $55.00 price target for the company. Thirteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $48.27.

IDEAYA Biosciences Stock Performance

IDYA stock traded down $0.43 during midday trading on Wednesday, hitting $33.29. 278,290 shares of the company’s stock were exchanged, compared to its average volume of 862,459. IDEAYA Biosciences, Inc. has a one year low of $20.90 and a one year high of $47.74. The company has a market cap of $2.52 billion, a PE ratio of -16.56 and a beta of 0.86. The stock’s fifty day moving average price is $38.86 and its 200-day moving average price is $40.68.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.02). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 20.09%. During the same period in the prior year, the firm posted ($0.49) EPS. The company’s revenue was down 100.0% compared to the same quarter last year. On average, analysts expect that IDEAYA Biosciences, Inc. will post -2.37 EPS for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.